Catalio Capital Management, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001958125

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q1 2026 · 41 positions · Total reported value $478.70M · Top-10 concentration 54.5% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 63.5% · 13 new · 14 cut · 6 exited

Active Share (vs S&P 500): 98.9% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q1 2026 13F filing, Catalio Capital Management, LP disclosed 41 equity positions with a combined reported value of $478.70M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 54.5% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2026 were DNTH ($47.02M), BBIO ($32.08M), ASND ($29.53M). By sector, the heaviest allocations are Health Care 89.4%, Other 10.6%. Versus the prior quarter, allocation shifted toward Other (+4.7pp) and away from Health Care (-4.7pp).

Versus the prior quarter, Catalio Capital Management, LP opened 13 new positions, trimmed 14 and fully exited 6, a turnover rate of 63.5% of positions. The portfolio's overlap with the prior quarter was 62% of names.

The largest new positions opened in Q1 2026 were DFTX ($19.62M), INCY ($17.14M), CRVS ($13.05M).

Of the 6 positions fully exited versus the prior quarter, the largest were LLY ($27.86M), JNJ ($25.01M), REGN ($23.00M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2026)

  • DFTX DEFINIUM THERAPEUTICS INC · $19.62M
  • INCY INCYTE CORP · $17.14M
  • CRVS CORVUS PHARMACEUTICALS INC · $13.05M
  • MANE VERADERMICS INC · $10.96M
  • KALV KALVISTA PHARMACEUTICALS INC · $8.59M
  • NAMS NEWAMSTERDAM PHARMA COMPANY · $2.67M
  • TYRA TYRA BIOSCIENCES INC · $2.58M
  • IMCR IMMUNOCORE HLDGS PLC · $2.54M

Fully Exited (vs previous quarter)

  • LLY ELI LILLY & CO · prev qtr: $27.86M
  • JNJ JOHNSON & JOHNSON · prev qtr: $25.01M · history
  • REGN REGENERON PHARMACEUTICALS · prev qtr: $23.00M
  • ISRG INTUITIVE SURGICAL INC · prev qtr: $15.41M
  • ADMA ADMA BIOLOGICS INC · prev qtr: $10.30M
  • ACLX ARCELLX INC · prev qtr: $10.18M
  • OCUL OCULAR THERAPEUTIX INC · prev qtr: $8.67M
  • OLMA OLEMA PHARMACEUTICALS INC · prev qtr: $6.68M

Insider Transactions (Form 4)

Latest Catalio Capital Management, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-10-16 Conversion Iambic Therapeutics, Inc. 742,546 — SEC filing
2026-10-16 Conversion Iambic Therapeutics, Inc. 1,458,290 — SEC filing
2026-10-16 Conversion Iambic Therapeutics, Inc. 1,995,749 — SEC filing

All insider transactions →

Fund Profile

Catalio Capital Management, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 46 US equity positions with a combined value of $535.82M. HoldingsHub carries 8 quarters of its filings (Q4 2024–Q3 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-121976 (status: Approved), registered 2021-07-30
  • Regulatory AUM (Form ADV): $1.93B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 78%, pooled investment vehicles 13%
  • Manages 23 private funds, of which 1 hedge funds

Portfolio Structure

  • 46 positions · $535.82M reported value (Q3 2026)
  • Top 10 holdings = 48.7% of reported value
  • Largest position: AVLN (AVALYN PHARMACEUTICALS INC) at 9.0%
  • Average position size: $11.65M

Sector Tilt

  • Health Care 96.3%
  • Industrials 2.8%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q3 2026: 13 new, 13 added, 14 reduced, 6 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 89.4%
Other 10.6%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 560.31K $47.02M 9.82%
9.82%
Reduce
2 432.01K $32.08M 6.70%
6.70%
Add
3 129.11K $29.53M 6.17%
6.17%
Add
4 420.73K $25.52M 5.33%
5.33%
Reduce
5 1.04M $24.38M 5.09%
5.09%
Reduce
6 163.91K $22.84M 4.77%
4.77%
Reduce
7 409.03K $21.56M 4.50%
4.50%
Add
8 1.04M $19.62M 4.10%
4.10%
New
9 577.81K $19.35M 4.04%
4.04%
Add
10 299.32K $18.78M 3.92%
3.92%
Reduce
11 850.80K $17.82M 3.72%
3.72%
Add
12 182.10K $17.14M 3.58%
3.58%
New
13 215.50K $14.20M 2.97%
2.97%
Reduce
14 70.91K $14.18M 2.96%
2.96%
Add
15 891.93K $13.05M 2.73%
2.73%
New
16 255.38K $12.31M 2.57%
2.57%
Add
17 439.04K $11.89M 2.48%
2.48%
Add
18 144.61K $11.58M 2.42%
2.42%
Reduce
19 173.58K $10.96M 2.29%
2.29%
New
20 722.78K $10.03M 2.10%
2.10%
Reduce
21 403.59K $9.82M 2.05%
2.05%
Add
22 426.55K $8.59M 1.79%
1.79%
New
23 491.12K $8.03M 1.68%
1.68%
Add
24 122.98K $7.86M 1.64%
1.64%
Add
25 294.36K $7.07M 1.48%
1.48%
Hold
26 47.19K $5.25M 1.10%
1.10%
Reduce
27 282.95K $5.13M 1.07%
1.07%
Reduce
28 1.64M $5.05M 1.05%
1.05%
Add
29 897.71K $5.00M 1.04%
1.04%
Add
30 62.02K $3.21M 0.67%
0.67%
Reduce
31 580.02K $3.02M 0.63%
0.63%
Reduce
32 247.77K $2.75M 0.57%
0.57%
Reduce
33 83.55K $2.67M 0.56%
0.56%
New
34 67.28K $2.58M 0.54%
0.54%
New
35 84.35K $2.54M 0.53%
0.53%
New
36 5.49M $2.51M 0.53%
0.53%
Hold
37 1.32M $1.43M 0.30%
0.30%
Hold
38 528.99K $708.85K 0.15%
0.15%
Hold
39 196.86K $696.88K 0.15%
0.15%
Hold
40 14.72K $463.91K 0.10%
0.10%
Hold
41 118.28K $454.19K 0.10%
0.10%
Hold

FAQ

What did Catalio Capital Management, LP buy in 2026-Q1?

In its 2026-Q1 13F filing, Catalio Capital Management, LP reported 41 equity positions worth $478.70M in aggregate; its largest disclosed positions were DNTH ($47.02M), BBIO ($32.08M), ASND ($29.53M).

How large is Catalio Capital Management, LP's portfolio?

Catalio Capital Management, LP reported $478.70M of long equity holdings across 41 positions as of 2026-Q1. Top-10 holdings account for 54.5% of reported value.

What is Catalio Capital Management, LP's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/catalio-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →